You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石藥業-B(02616.HK)在2022年ESMO Asia年會上公佈普吉華(普拉替尼膠囊)®治療RET融合陽性非小細胞肺癌中國患者的更新研究數據
格隆匯 12-05 08:03

格隆匯12月5日丨基石藥業-B(02616.HK)發佈公吿,公司在2022年歐洲腫瘤內科學會亞洲峯會(ESMO Asia)上公佈了ARROW研究普吉華(普拉替尼膠囊)治療轉染重®排(「RET」)融合陽性非小細胞肺癌(「NSCLC」)中國患者的療效和安全性更新數據。數據顯示:普吉華®在RET融合陽性局部晚期或轉移性NSCLC中國患者具有優越和持久的臨牀抗腫瘤活性,整體安全可控。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account